Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acitretin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Acitretin | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Any nondermatologic medication. Patients must have: * HIV infection. * Psoriasis involving at least 10 percent of body surface.
Top 20 of 28 competitors
Acitretin is a small molecule being studied for the treatment of HIV Infections, specifically in patients who also have psoriasis. It is currently in Phase 3 clinical development and is being developed by Roche Holding AG. The drug is investigational and not yet approved for this use.
Acitretin is a retinoid that works by modulating cellular differentiation and proliferation. It does not target a specific molecular target but rather acts through retinoid receptors to regulate gene expression. This mechanism is relevant to its potential effect on psoriasis in HIV-positive patients.
Acitretin is being developed by Roche Holding AG, a multinational healthcare company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in HIV-positive patients with psoriasis. Roche's stock is traded under the ticker RHHBY.
Acitretin is currently in Phase 3 clinical development for the treatment of HIV Infections. It is an investigational drug and has not been approved by regulatory authorities for this indication. The ongoing Phase 3 trial is completed, with results expected to inform further development.
Acitretin has one completed Phase 3 clinical trial with the identifier NCT00002143, titled 'Treatment of Psoriasis Using Acitretin in HIV-Positive Patients.' This trial enrolled 30 participants in the United States and was an uncontrolled, non-randomized study. The trial included adults aged 18 years and older.
Acitretin is a retinoid, a class of compounds related to vitamin A. It is distinct from other retinoids like isotretinoin or tretinoin, though they share similar mechanisms of action. Acitretin is specifically being studied for its potential benefits in HIV-positive patients with psoriasis.